ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

NCI RFAs Available

May 5, 2000

NTP Board Okays concept for New In Vitro study Using Oncogenes

May 10, 1985

Rabson Recommended For NCI Acting Director, Will be Top Prospect For Permanent Appointment

August 26, 1988

Two Groups Take Different Approaches To Managing Toxicity Of Saltz Regimen.

June 22, 2001

NCAB To Seek Changes In Cancer Act Renewal, Budget Improvements

November 20, 1987

NIH RFA Available

August 3, 2001